INTRODUCTION {#s1}
============

Thiamine metabolism dysfunction syndrome 2 (MIM: 607483) is an autosomal recessive neurometabolic condition, resulting from mutations in the solute carrier family 19, member 3 (*SLC19A3*, MIM: 606152) gene, which encodes the human thiamine transporter 2 (hTHTR2) ([@WHITFORDMCS001909C46]). The disease was first described in children of consanguineous parents, mainly of Saudi Arabian descent ([@WHITFORDMCS001909C36]). The causative mutation for the disease was subsequently mapped to the *SLC19A3* gene in 2005 ([@WHITFORDMCS001909C60]). The disease typically presents with recurrent bouts of subacute encephalopathy, confusion, seizures, dysarthria, dysphagia, and dystonia, progressing to coma and death in early childhood to adolescence ([@WHITFORDMCS001909C36]; [@WHITFORDMCS001909C48]); however, clinical manifestations in infancy have also been reported ([@WHITFORDMCS001909C45]; [@WHITFORDMCS001909C59]).

Magnetic resonance imaging (MRI) analysis reveals lesions and necrosis in the caudate nucleus and putamen, with involvement of the infra and supratentorial brain cortex, and the brainstem ([@WHITFORDMCS001909C36]; [@WHITFORDMCS001909C48]). Most individuals display normal biochemical and metabolic markers; however, increased levels of lactate and pyruvate in the serum and cerebrospinal fluid (CSF) and increased levels of amino acids in the serum and urine have been observed in a minority of cases ([@WHITFORDMCS001909C36]; [@WHITFORDMCS001909C7]; [@WHITFORDMCS001909C3]; [@WHITFORDMCS001909C11]; [@WHITFORDMCS001909C13]; [@WHITFORDMCS001909C14]; [@WHITFORDMCS001909C25]; [@WHITFORDMCS001909C37]; [@WHITFORDMCS001909C48]; [@WHITFORDMCS001909C34], [@WHITFORDMCS001909C35]; [@WHITFORDMCS001909C43]; [@WHITFORDMCS001909C45]; [@WHITFORDMCS001909C59]).

*SLC19A3* belongs to a family of solute carrier genes that includes solute carrier family 19, member 1 (*SLC19A1*) encoding reduced folate transporter (RFC-1), and solute carrier family 19, member 2 (*SLC19A2*) encoding thiamine transporter 1 (hTHTR1) ([@WHITFORDMCS001909C10]). Together, *SLC19A2* and *SLC19A3* are responsible for transportation and homeostasis of thiamine, also known as vitamin B~1~. Thiamine is not endogenously synthesized but is obtained from the diet via absorption through the small intestine. A number of thiamine-dependent enzymes are required for normal cellular function, including oxidative metabolism through the connection of glycolysis with the tricarboxylic acid (TCA) cycle via pyruvate dehydrogenase, the TCA cycle via the α-ketoglutarate complex, and the pentose phosphate shunt ([@WHITFORDMCS001909C23]). Although individuals with BTBGD have defective or nonfunctional versions of *SLC19A3*, they do not experience global thiamine deficiency, showing normal levels of thiamine in the blood; however, levels of free-thiamine in the CSF are often significantly reduced ([@WHITFORDMCS001909C35]).

Expression of SLC19A3 is ubiquitous ([@WHITFORDMCS001909C53]; [@WHITFORDMCS001909C56]), with expression in the brain restricted to the blood vessels. Specifically, the transporter is localized at the basement membrane and within the perivascular pericytes ([@WHITFORDMCS001909C25]). In contrast, SLC19A2 is localized to the luminal side of the endothelial cells of the brain. This stark polarization of the two transporters in the brain differs from their localization in the peripheral tissues (namely, the intestines and kidneys), where SLC19A3 is found at the luminal apical side, whereas SLC19A2 is found both at the luminal and basolateral sides of these organs to maintain levels in the blood ([@WHITFORDMCS001909C42]; [@WHITFORDMCS001909C5]; [@WHITFORDMCS001909C47]). The polarization of the two thiamine transporters in the brain but not the kidney or intestine suggests that both transporters are required for transport of thiamine across the blood brain barrier, and it may explain why individuals harboring *SLC19A3* gene mutations develop neurological symptoms and pathology, without having a systemic thiamine deficiency.

[@WHITFORDMCS001909C36] reported that BTBGD patients responded to high doses of biotin with symptoms disappearing within days, with no further episodes of seizures, dystonia, confusion, or coma. Furthermore, clinical signs return to near baseline if treatment is initiated early enough ([@WHITFORDMCS001909C36]; [@WHITFORDMCS001909C27]; [@WHITFORDMCS001909C7]; [@WHITFORDMCS001909C3]; [@WHITFORDMCS001909C49]). Early diagnosis is therefore essential, as permanent neurological sequelae including epilepsy, mental retardation, dystonia, and eventually death can occur if left untreated ([@WHITFORDMCS001909C7]; [@WHITFORDMCS001909C3]; [@WHITFORDMCS001909C48]; [@WHITFORDMCS001909C13]; [@WHITFORDMCS001909C59]).

Biotin is not a substrate for the thiamine transporter ([@WHITFORDMCS001909C46]); thus the method of action for the response to biotin supplementation is unclear. The initial study by Ozand et al. reported no effect of thiamine alone on the clinical presentation of the patients; however, there are conflicting reports as to the effectiveness of biotin or thiamine alone ([@WHITFORDMCS001909C27]; [@WHITFORDMCS001909C7]; [@WHITFORDMCS001909C58]; [@WHITFORDMCS001909C3]; [@WHITFORDMCS001909C14]; [@WHITFORDMCS001909C45]; [@WHITFORDMCS001909C49]). Most current treatment protocols use a combination of both biotin and thiamine. There is limited physiological understanding as to the rationale behind this treatment approach. It has been suggested that thiamine and biotin act synergistically in the treatment of BTBGD ([@WHITFORDMCS001909C59]), and there is evidence that biotin is required for the transcription of the *SLC19A3* gene ([@WHITFORDMCS001909C57]). Thiamine-induced expression of an alternate thiamine transporter (encoded by the *SLC19A2* gene) has been suggested to underlie the clinical benefit seen in BTBGD patients ([@WHITFORDMCS001909C27]; [@WHITFORDMCS001909C14]); however, this has not yet been supported by experimental evidence ([@WHITFORDMCS001909C32]).

Disease-associated variants, both homozygous and compound heterozygous, have been reported throughout the gene ([Table 1](#WHITFORDMCS001909TB1){ref-type="table"}), and the effect on localization and activity of SLC19A3 has been investigated for a number of mutations. There are mutations that prevent the transport of the SLC19A3 protein to the cell surface, and others that reduce the affinity of the transporter for thiamine by either eliminating or reducing the functional capacity of the transporter ([@WHITFORDMCS001909C46]; [@WHITFORDMCS001909C27]; [@WHITFORDMCS001909C43]).

###### 

Previously reported variants in *SLC19A3*

  Chromosomal variant                 Protein variant   Number of patients   Domain   Paper(s)
  ----------------------------------- ----------------- -------------------- -------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Amino acid substitutions                                                            
  c.68G\>T                            p.G23V            6                    TM1      [@WHITFORDMCS001909C25]; [@WHITFORDMCS001909C35]; [@WHITFORDMCS001909C37]; [@WHITFORDMCS001909C38]; [@WHITFORDMCS001909C60]
  c.130A\>G                           p.K44E            2                    Ext1     [@WHITFORDMCS001909C27]
  c.153A\>G                           p.I51M            1                    Ext1     [@WHITFORDMCS001909C35]
  c.157A\>G                           p.N53D            1                    Ext1     [@WHITFORDMCS001909C35]
  c.280T\>C                           p.W94R            2                    TM3      [@WHITFORDMCS001909C43]
  c.337T\>C                           p.Y113H           3                    TM4      [@WHITFORDMCS001909C13]
  c.416T\>A                           p.V139G           1                    Int3     [@WHITFORDMCS001909C12]
  c.517A\>G                           p.N173D           1                    TM6      [@WHITFORDMCS001909C11]
  c.527C\>A                           p.S176Y           1                    TM6      [@WHITFORDMCS001909C25]
  c.541T\>C                           p.S181P           3                    TM6      [@WHITFORDMCS001909C13]; [@WHITFORDMCS001909C25]
  c.958G\>C                           p.E320Q           2                    TM8      [@WHITFORDMCS001909C27]; [@WHITFORDMCS001909C58]
  c.1154T\>G                          p.L385R           2                    TM10     [@WHITFORDMCS001909C25]
  c.1196A\>T                          p.N399I           1                    Int6     [@WHITFORDMCS001909C26]
  c.1264 A\>G                         p.T422A           63                   TM11     [@WHITFORDMCS001909C3]; [@WHITFORDMCS001909C4]; [@WHITFORDMCS001909C9]; [@WHITFORDMCS001909C35]; [@WHITFORDMCS001909C49], [@WHITFORDMCS001909C48]; [@WHITFORDMCS001909C60]
  c.1332C\>G                          p.S444R           1                    TM12     [@WHITFORDMCS001909C25]
  Others                                                                              
  Chr2: 228,568,440--228,613,489del                     2                             [@WHITFORDMCS001909C13]
  c.20C\>A                            p.S7\*            5                             [@WHITFORDMCS001909C14]
  c.74dup                             p.S26fs           9                             [@WHITFORDMCS001909C45]
  c.81_82dup                          p.M28fs           1                             [@WHITFORDMCS001909C45]
  c.507C\>G                           p.Y169\*          1                             [@WHITFORDMCS001909C25]
  c.1173--3992_1314 + 41del4175       p.Q393\*fs        2                             [@WHITFORDMCS001909C43]
  r.1173_1314del                      p.E393\*          1                             [@WHITFORDMCS001909C25]
  c.895_925del                        p.V299fs          2                             [@WHITFORDMCS001909C25]
  c.980-14 A\>G                       p.Y327DfsX8       7                             [@WHITFORDMCS001909C7]; [@WHITFORDMCS001909C34]; [@WHITFORDMCS001909C35]; [@WHITFORDMCS001909C44]
  c.982del                            p.A328Lfs\*10     2                             [@WHITFORDMCS001909C18]
  c.1079dupT                          p.L360Ffs\*38     1                             [@WHITFORDMCS001909C34]
  c.1403delA                                            2                             [@WHITFORDMCS001909C59]

TM, transmembrane domain; Ext, extracellular domain; Int, intracellular domain.

There is an apparent trigger for episodes of illness that can be identified in up to 50% of children with BTBGD ([@WHITFORDMCS001909C48]). Bouts of decompensation are often preceded by febrile illness or mild trauma ([@WHITFORDMCS001909C36]; [@WHITFORDMCS001909C48]; [@WHITFORDMCS001909C34]; [@WHITFORDMCS001909C59]). This indicates that there is a background level of thiamine that is transported in the cell with a dysfunctional SLC19A3 transporter that is able to support the energy needs of the brain during normal conditions. There is evidence to suggest the decline and clinical manifestation of the disorder may occur when the energy required exceeds the background levels and there is an inability of the mutant form of the *SLC19A3* gene to undergo the normal stress-induced expression and functional compensation ([@WHITFORDMCS001909C43]; [@WHITFORDMCS001909C35]).

Here we report two siblings who first presented with decompensation, encephalopathy, and seizures following febrile illness. They were subsequently diagnosed with BTBGD following whole-genome sequencing (WGS), which identified compound heterozygous inheritance of a previously reported missense mutation, p.G23V, and a novel 4808-bp promoter deletion. This deletion is the smallest promoter deletion reported for this gene to date, further defining the minimal promoter region for this gene in the context of the disease.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The two cases are siblings, New Zealand--born from nonconsanguineous parents of mainly European descent. The proband (AM1005) died at 20 yr of age as a result of respiratory complications of severe dystonic spastic quadriplegia. He was born after a normal pregnancy, had Apgar scores of 5 at 1 min and 9 at 5 min and had 3 d in hospital for treatment of transient tachypnea of the newborn. He progressed normally in his development until he presented at 9 mo of age with seizures in the context of a viral illness. His brain MRI (not shown) revealed bilateral basal ganglia T2 hyperintensity and subdural hematomas. Subsequently he developed epilepsy and three further episodes of definite regression and encephalopathy. Follow-up brain MRI revealed involvement of the basal ganglia, caudate head, lentiform nuclei, and white matter atrophy. From approximately 12 yr of age he was essentially dependent for all activities of daily living but bright and aware of his surroundings. He had extensive neurometabolic workup in 2008 and had mild complex IV deficiency on muscle biopsy. All other investigations were normal and a tentative diagnosis of mitochondrial disease was made.

AM1006 is the proband\'s full sibling and is currently 7 yr of age. She was born after a normal pregnancy and had normal development until ∼6 mo of age. By 2 yr she had a diagnosis of autism spectrum disorder. She could walk but was ataxic. At nearly 4 yr of age, after a period of steady development, she developed progressive problems with feeding and encephalopathy in the context of a febrile illness. Brain MRI revealed acute restricted diffusion and swelling of the putamen and caudate nuclei ([Fig. 1](#WHITFORDMCS001909F1){ref-type="fig"}B). She was treated with a "mitochondrial cocktail" that included thiamine and improved. This was subsequently withdrawn after 6 mo as its effectiveness was not clear and pyruvate dehydrogenase deficiency was excluded. At 6 yr of age she had a prolonged period of neurological deterioration associated with a markedly abnormal brain MRI ([Fig. 1](#WHITFORDMCS001909F1){ref-type="fig"}C). She lost her ability to swallow and mobilize independently. Given the severity of her presentation she was again trialed on a short course of thiamine and improved. Prior to her diagnosis being made she was gastrostomy-fed, had excessive drooling, was unable to mobilize independently, was hypotonic, and was very irritable. Clinical features of both patients are summarized in [Table 2](#WHITFORDMCS001909TB2){ref-type="table"}.

![Magnetic resonance images taken from AM1006. (*A*) Axial T2 brain MRI taken at 3 yr and 5 mo of age prior to the first presentation. (*B*) Axial T2 brain MRI taken during first encephalopathy presentation at 3 yr and 9 mo of age: bilateral symmetrical T2 hyperintensity, swelling, and edema within the caudate nuclei and putamina sparing the globi pallidi and thalami. (*C*) Axial T2 brain MRI taken at 6 yr and 1 mo of age, during the second period of encephalopathy: bilateral symmetrical T2 hyperintensity within caudate nuclei, putamina, thalami, and subcortical white matter of the frontal lobes. There is resolution of basal ganglia swelling relative to the first degenerative episode (*B*).](WhitfordMCS001909_F1){#WHITFORDMCS001909F1}

###### 

Clinical summary of BTBGD in patients AM1005 and AM1006

                                                          AM1005                                    AM1006                                                                                                                       AM1006 post-treatment
  ------------------------------------------------------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -----------------------
  Subacute encephalopathy                                                                                                                                                                                                        
  Confusion                                               Yes                                       Yes                                                                                                                          Nil further events
  Dysarthria                                              Yes                                       Yes                                                                                                                          Nil further events
  Dysphagia                                               Yes                                       Yes                                                                                                                          Nil further events
  Reduced level of consciousness                          Yes                                       Yes                                                                                                                          Nil further events
  Chronic symptoms                                                                                                                                                                                                               
  Dysphagia                                               Yes                                       Yes                                                                                                                          Resolved
  Spasticity                                              Yes                                       No                                                                                                                           No
  Dystonia                                                Yes                                       No                                                                                                                           No
  Quadriparesis                                           Yes                                       No                                                                                                                           No
  Inability to walk                                       Yes                                       Yes                                                                                                                          Improving
  Inability to speak                                      Yes                                       Yes                                                                                                                          Improving
  Seizures                                                Yes                                       Yes                                                                                                                          No
  Severe gait ataxia                                      N/A---immobile                            Severe                                                                                                                       Moderate
  Nystagmus                                               No                                        No                                                                                                                           No
  Ophthalmoplegia                                         No                                        No                                                                                                                           No
  Developmental delay                                     Yes                                       Yes                                                                                                                          Improving
  Biochemical studies of intermediary metabolism normal   Yes                                       Yes                                                                                                                          N/A
  Bacterial studies normal                                Yes                                       Yes                                                                                                                          N/A
  Viral studies normal                                    Yes                                       Yes                                                                                                                          N/A
  Preceded by immune response to illness or trauma        Yes                                       Yes                                                                                                                          N/A
  Radiological features                                                                                                                                                                                                          
  Swelling and T2 hyperintensity                                                                                                                                                                                                 
  Basal ganglia                                           Yes                                       Yes                                                                                                                          N/A
  Thalami                                                 No                                        Yes                                                                                                                          N/A
  Subcortical white matter                                No                                        Yes                                                                                                                          N/A
  Cortex                                                  No                                        Yes                                                                                                                          N/A
  Cerebral white matter                                   No                                        Yes                                                                                                                          N/A
  Cortex                                                  No                                        Yes                                                                                                                          N/A
  Midbrain                                                No                                        Yes                                                                                                                          N/A
  Necrosis of                                                                                                                                                                                                                    
  Head of basal ganglia                                   Yes                                       Yes                                                                                                                          N/A
  Putamen                                                 Yes                                       Yes                                                                                                                          N/A
  Novel clinical features                                                                                                                                                                                                        
                                                          Subdural hematomas present on brain MRI   Autism spectrum disorder diagnosed preencephalopathic event with normal initial MRI scan, choreoathetoid movement disorder   

Genomic Analyses {#s2b}
----------------

Genetic investigation was performed under the hypothesis that the affected siblings carry the same causative variant(s). The siblings were first assessed for copy-number variants using an Affymetrix CytoScan 750K Cytogenetics Array (analyzed using ChAS v.1.2/na32.1 software). Two shared regions of loss of heterozygosity (LOH) were identified; 3.5 Mb at 2p12p11.2 (hg19 Chr2:81,640,336--85,127,909) and 3.2 Mb at 19p13.2 (hg19 Chr19:9,917,692--13,157,540). The first region of LOH encompasses the succinate-CoA ligase, α-subunit (*SUCLG1*) gene that encodes the α-subunit of the enzyme succinate coenzyme A ligase, an enzyme involved in the TCA cycle. Autosomal recessive mutations in this gene result in mitochondrial DNA depletion syndrome 9 (MTDPS9, MIM: 245400) ([@WHITFORDMCS001909C41]). The symptoms of MTDPS9 were similar to those observed in the two siblings; however, the lack of methylmalonic acid in the urine excluded the 2p12p11.2 LOH as the causative variant.

The second region of LOH contained only one gene: glutaryl CoA dehydrogenase (*GCDH*) which encodes a protein of the same name, involved in the metabolism of lysine, hydroxylysine, and tryptophan. Mutations in this gene result in glutaric acidemia type I (GA1, MIM: 231670) ([@WHITFORDMCS001909C19]). GA1 was initially considered in the proband to be a strong candidate due to phenotypic similarities; however, urine organic acids, acylcarnitine profile, and enzymology in skin fibroblasts were normal, suggesting that the 19p13.2 was not the causative variant in the patients.

Whole-genome sequencing was performed on genomic DNA from both children, with sequencing statistics detailed in [Table 3](#WHITFORDMCS001909TB3){ref-type="table"}. 166,057 single-nucleotide and indel variants were discovered in the exonic and splice regions of both children. Synonymous variants, variants present in only one sibling, and variants exceeding a frequency of 0.01 in any of the ExAC, HapMap, or 1000 Genomes Project populations were excluded from further consideration. ([@WHITFORDMCS001909C54]; [@WHITFORDMCS001909C52]; [@WHITFORDMCS001909C28]). Further filtering of the remaining 3481 variants was performed based on protein location, functional impact of the variant, its mode of inheritance (homozygous or compound heterozygous), as well as the biological relevance of the gene. This supervised exclusion of variants revealed compound heterozygous mutations in the *SCL19A3* gene*.* The first is a heterozygous missense mutation, c.68G\>T (GRCh37 Chr2:228,566,967; NM_025243.3:c.68G\>T) resulting in a glycine-to-valine change (p.G23V) (summarized in [Table 4](#WHITFORDMCS001909TB4){ref-type="table"}). The amino acid is conserved across species to *Drosophila melanogaster* and *Caenorhabditis elegans* (BLASTp, [@WHITFORDMCS001909C15]). The allele is also extremely rare, present at a frequency of 0.000008239 representing one individual of South Asian descent in the ExAC database ([@WHITFORDMCS001909C28]), with no homozygotes present at this position. Confirmation of the single-nucleotide variant in both children and their parents was performed using polymerase chain reaction (PCR) and Sanger sequencing, which verified the mutation was inherited from the mother, who was also heterozygous ([Fig. 2](#WHITFORDMCS001909F2){ref-type="fig"}). The phenotypic presentation in the children corresponded to the description of BTBGD in the literature; however, no other candidate SNP or indels in *SLC19A3* were identified.

![Family pedigree and corresponding Sanger sequencing electropherograms showing the transmission of the c.68G\>T mutation and Chr2: 228,582,252--228,587,059 deletion in the *SLC19A3* gene. The breakpoints for the deletion are indicated by the black arrows, with an insertion of a single base, cytosine, at the breakpoint indicated by the red box. No PCR product was amplifiable from the mother who did not contain the deletion as the PCR was optimized for the 1481-bp deleted product.](WhitfordMCS001909_F2){#WHITFORDMCS001909F2}

###### 

Sequencing statistics for whole-genome analysis

  Individual   Total read pairs   Total mapped reads   Average coverage   Reads at 25 plus coverage   Coverage at SNP   Average coverage over deletion
  ------------ ------------------ -------------------- ------------------ --------------------------- ----------------- --------------------------------
  AM1005       541,331,895        806,382,669          38.8               99.2%                       42                14.5
  AM1006       569,003,503        765,493,391          36.1               98.8%                       32                16.5

###### 

SLC19A3 variant summary

  Gene        Chromosome   HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect            ClinVar ID     Parent of origin   Break points
  ----------- ------------ -------------------- ------------------------ -------------- --------------------------- -------------- ------------------ --------------------------
  *SLC19A3*   2            NM_025243.3          Gly23                    Missense       Gly\>Val                    SCV000574715   Mother             
  *SLC19A3*   2            NC_000002.11                                  Deletion       Critical promoter deleted   SCV000574716   Father             228,582,251--228,587,060

To investigate the *SLC19A3* locus for structural variants, the WGS read alignments were visualized with Integrated Genomics Viewer (IGV, 2.3.55) (<http://software.broadinstitute.org/software/igv>; [@WHITFORDMCS001909C55]) and inspected for regions of altered coverage and alignment of discordant read pairs. This identified a region of reduced coverage, bordered by discordant reads encompassing exon 1 encoding the 5′ untranslated region (5′ UTR) ([Fig. 3](#WHITFORDMCS001909F3){ref-type="fig"}). The candidate deletion was also detected by copy-number variant detection algorithms: CNVnator (based on alterations in read depth) and BreakDancer (based on paired-end information) ([@WHITFORDMCS001909C6]; [@WHITFORDMCS001909C2]). The precise breakpoints were mapped by PCR and Sanger sequencing to GRCh37 Chr2:228,582,251--228,587,060 (NC_000002.11:g.228,582,251--228,587,060 del) with the insertion of a cytosine nucleotide (summarized in [Table 4](#WHITFORDMCS001909TB4){ref-type="table"}). This 4808-bp deletion is present in both children and PCR analysis confirmed inheritance from the father. We hypothesize that this deletion abolishes the activity of the promoter, thus eliminating expression from this allele. RNA-seq analysis of RNA from fibroblasts of the surviving child, AM1006, and three unrelated controls did not detect any reads mapping to the *SLC19A3* gene; in contrast *SLC19A1* and *SLC19A2* were well expressed in all samples. Thus, we were unable to categorically determine the effect of the deletion on *SLC19A3* gene expression.

![Deletion in *SLC19A3*. Integrated Genomics Viewer showing depth of coverage of WGS reads across the 4808-bp deletion (red bar) for both siblings and an unrelated control. The arrows denote the breakpoints for this deletion. The blue bar denotes the 45,049-bp deleted region reported by [@WHITFORDMCS001909C13], whereas the green bar denotes the minimal promoter region defined by [@WHITFORDMCS001909C31].](WhitfordMCS001909_F3){#WHITFORDMCS001909F3}

Thus, the two cases harbor compound heterozygous inherited mutations in the *SLC19A3* gene; a maternally inherited heterozygous p.G23V and a paternally inherited 4808-bp heterozygous deletion in the 5′ region between Chr2:228,582,251 and Chr2:228,587,060, confirming the diagnosis of BTBGD.

Treatment Outcomes {#s2c}
------------------

Following the detection of the *SLC19A3* gene mutations, AM1006 was commenced on high-dose (20-mg/kg/day) thiamine and (15-mg/kg/day) biotin at the age of 6 yr and 9 mo. Ten months post commencement of therapy she is now running independently, eating a full diet, and no longer requiring gastrostomy for nutrition. She has had no further encephalopathic events and is communicating with noises and making excellent cognitive progress. She remains intellectually disabled and has autism but is more engaged and interactive and making weekly gains in her development.

DISCUSSION {#s3}
==========

Analysis of WGS data resulted in a molecular diagnosis of BTBGD for two siblings with progressive neurodegeneration. This diagnosis led to successful biotin/thiamine treatment for the surviving child. Both cases harbor compound heterozygous mutations in the *SLC19A3* gene, one inherited from each unaffected parent.

One of the mutations had previously been reported for multiple families with BTBGD, c.68G\>T, p.G23V ([Table 1](#WHITFORDMCS001909TB1){ref-type="table"}), whereas the other is a novel 4808-bp deletion encompassing the first exon and predicted promoter region. This deletion is within the much larger 45-kb deletion recently reported by [@WHITFORDMCS001909C13] and includes the minimal promoter region for the *SLC19A3* gene ([Fig. 3](#WHITFORDMCS001909F3){ref-type="fig"}; [@WHITFORDMCS001909C31]). The deletion reported in this study is currently the smallest promoter deletion in this gene identified, further defining the critical promoter region. Taken together, these data suggest that the deletion results in reduced or no expression from this allele. From a molecular diagnostic perspective, the deletion is too small to be detected by aCGH and would have been missed by typical WES approaches (for review, see [@WHITFORDMCS001909C51]).

The other mutation (p.G23V) lies within the first transmembrane domain of hTHTR2 ([Fig. 4](#WHITFORDMCS001909F4){ref-type="fig"}), a position that is highly conserved through to invertebrates. The p.G23V mutant SLC19A3 protein has been shown to have minimal effect on targeting of the protein to apical surface of cells, but effectively abolishes the ability of the protein to transport thiamine across the cell membrane ([@WHITFORDMCS001909C46]). Based on crystallographic and experimental data of other transporter proteins, the transmembrane domain 1 of *SLC19A3* is one of the four tilted helices that are crucial for the shape and activity of the central hydrophobic pore ([@WHITFORDMCS001909C50]; [@WHITFORDMCS001909C20]; [@WHITFORDMCS001909C1]; [@WHITFORDMCS001909C21]; [@WHITFORDMCS001909C16]). There is an overrepresentation of glycine in membrane spanning proteins where the helices interact ([@WHITFORDMCS001909C22]), and substitutions with larger amino acids such as valine in this case may result in steric hindrance in the mutated protein, resulting in conformational changes ([@WHITFORDMCS001909C46]). The detrimental effect of glycine-to-valine substitutions has been reported for multiple other solute carrier transporters, resulting in decreased transporter function ([@WHITFORDMCS001909C61]; [@WHITFORDMCS001909C30]).

![Topography of the hTHTR2 protein, consisting of 12 transmembrane domains. Point mutations reported in the literature are indicated as per the legend. The pG23V mutation identified in this study is indicated in red. The topography map is generated from Protter ([@WHITFORDMCS001909C33]).](WhitfordMCS001909_F4){#WHITFORDMCS001909F4}

Confirming previous reports, the surviving patient responded positively to thiamine and biotin treatment. The exact mechanism through which biotin and thiamine ameliorate the symptoms of BTBGD is unknown. The minimal promoter region for both the *SLC19A2* and *SLC19A3* genes has been previously identified ([@WHITFORDMCS001909C40]; [@WHITFORDMCS001909C39]; [@WHITFORDMCS001909C31]). Both promoters contain binding sites for the transcription factor Specificity Protein 1 (SP1), and binding increases the transcription of both genes. Specificity Protein 3 (SP3) binding to the minimal promoter of *SLC19A3* also increases transcription of the gene ([@WHITFORDMCS001909C31]). Biotin supplementation of cells in culture increases the nuclear abundance of both SP1 and SP3, as well as their association with the respective DNA binding sites, with consequential increases in transcription ([@WHITFORDMCS001909C17]). Therefore, biotin\'s therapeutic effect may be through an indirect transcriptional activation of the *SLC19A2* and *SLC19A3* genes via SP1 and SP3. This proposed method of action for biotin treatment of BTBGD is in agreement with the hypothesis that the disease is caused by an inability of neurons to undergo a stress-induced increase in *SLC19A3* gene expression ([@WHITFORDMCS001909C43]). An increase in SP1 expression has been shown to result in the differential up-regulation of *SLC19A3* gene transcription and not *SLC19A2* ([@WHITFORDMCS001909C32]). Therefore, supplementation of biotin may result in increased transport of thiamine through a semifunctional *SLC19A3* allele ([@WHITFORDMCS001909C25]).

Critically, the application of WGS was required to detect the small promoter deletion, which lay below the thresholds of detection using conventional high-resolution array-based genome analysis and WES. The identification of the variants reported here resulted in a refined and precise molecular diagnosis and subsequent treatment for the surviving child via supplementation of biotin and thiamine. Early detection and treatment of BTBGD is critical for the long-term survival and outcome for patients. Therefore, these results provide strong support for the expeditious use of WGS in the diagnosis of rare neurodevelopmental disorders.

METHODS {#s4}
=======

DNA Extraction {#s4a}
--------------

DNA was extracted from peripheral blood EDTA samples using Gentra Puregene DNA Extraction kit (QIAGEN), according to the manufacturer\'s instructions.

aCGH Analysis {#s4b}
-------------

Genome-wide copy number and SNP analysis was undertaken using an Affymetrix CytoScan 750K Array, according to the manufacturer\'s instructions. Regions of copy-number change and LOH were determined using the Affymetrix Chromosome Analysis Suite software (ChAS) v.1.2/na32.1 and interpreted with the aid of the UCSC genome browser (<http://genome.ucsc.edu/>; Human Feb. 2009 GRCh37/hg19 assembly).

Whole-Genome Sequencing {#s4c}
-----------------------

WGS services were provided by The Kinghorn Centre for Clinical Genomics (KCCG) at the Garvan Institute using the Illumina HiSeq X Ten instrument. Reads were mapped with Burrows--Wheeler aligner (v 0.7.12) ([@WHITFORDMCS001909C29]) to the 1000 Genomes human genome reference sequence (GRCh37.p13), sequencing statistics in [Table 3](#WHITFORDMCS001909TB3){ref-type="table"}. After removal of optical and PCR duplicates, indels were realigned and base quality scores were recalibrated using the Genome Analysis Toolkit (v. 3.4-0) ([@WHITFORDMCS001909C8]). The alignments for the two children were combined with alignments from 14 unrelated individuals for joint variant discovery with the GATK\'s HaplotypeCaller and GenotypeGVCFs tools, followed by variant quality score recalibration according to the Broad Institute\'s Best Practices ([@WHITFORDMCS001909C8]).

Population frequency of SNV and indel variants were obtained from the Exome Aggregation Consortium (ExAC) ([@WHITFORDMCS001909C28]), HapMap ([@WHITFORDMCS001909C54]), and 1000 Genomes Projects ([@WHITFORDMCS001909C52]). Bioinformatic identification of CNVs was performed using default parameters of BreakDancer (v 1.4.5) ([@WHITFORDMCS001909C6]) and CNVnator (v 0.3) ([@WHITFORDMCS001909C2]).

WGS alignments and regional variation in read coverage were viewed using the Integrated Genomics Viewer (IGV, 2.3.55) (<http://software.broadinstitute.org/software/igv>; [@WHITFORDMCS001909C55]). Discordant read pairs (pairs mapped further apart than the average library fragment size) were identified with IGV.

Sanger Sequencing {#s4d}
-----------------

Confirmation of variants was performed using PCR and Sanger sequencing. The forward primer 5′ TTGAGGGAAGCCCTGTATCC 3′, and the reverse primer 5′ GCAGTTCCTGGATTTACCCC 3′ generated a 204-bp product using the Expand High Fidelity PCR System (Roche) with the following thermocycler conditions: 2 min initial denaturation at 94°C, with 30 cycles of 15-sec denaturation at 94°C, 30 sec of annealing at 50°C, and 45 sec of extension at 72°C, followed by 7 min of final extension at 72°C. This 205-bp product includes the C\>G missense mutation. The forward primer 5′ TTGCGGCAGCGACATTGATT 3′, and the reverse primer 5′ TGTGCTCGTCTACACATCTTCC 3′ were designed to generate a 6289-bp product in the wild-type allele, and a 1481-bp product in the deleted allele. Thermocycler conditions were optimized so that only the deleted copy was exponentially amplified; 2 min of initial denaturation at 94°C, with 30 cycles of 15-sec denaturation at 94°C, 30 sec annealing at 50°C, and a 3-min extension at 72°C, followed by a 7-min final extension at 68°C. Sanger sequencing was performed by the Genomics Centre, Auckland Science Analytical Services, The University of Auckland, New Zealand. Sanger sequencing data were viewed using Geneious (8.1.5) (<http://www.geneious.com>; [@WHITFORDMCS001909C24]).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Consent was not obtained to deposit full variant calling data publicly; however, mutations have been deposited to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar>) under the accession numbers SCV000574715 and SCV000574716.
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